Citi analyst David Lebowitz raised the firm’s price target on BridgeBio (BBIO) to $67 from $58 and keeps a Buy rating on the shares. The firm updated commercial stage biotechnology targets into the Q2 reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- Microsoft upgraded, Instacart initiated: Wall Street’s top analyst calls
- Oppenheimer upgrades BridgeBio on execution, data catalysts
- BridgeBio upgraded to Outperform from Perform at Oppenheimer
- BridgeBio Pharma Enters Royalty Purchase Agreement
- Strategic Financial Maneuvers and Growth Potential: BridgeBio Pharma’s Path to Profitability